Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 19/20 | 0.59 |
| ▸ | BMPR1A | P36894 | 13/20 | 0.59 |
| ▸ | ACVRL1 | P37023 | 9/20 | 0.59 |
| ▸ | ACVR1B | P36896 | 8/20 | 0.59 |
| ▸ | BMPR1B | O00238 | 8/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17442217 | 0.90 | ACVR1 (0.72) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL19110500 | 0.85 | ACVR1 (0.61) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL19110497 | 0.84 | ACVR1 (0.53) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL17531602 | 0.84 | ACVR1 (0.82) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL23988922 | 0.82 | KDR (0.54) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL17442056 | 0.82 | ACVR1 (0.50) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL17442054 | 0.82 | ACVR1 (0.50) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL17531597 | 0.80 | ACVR1B (0.81) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL26867234 | 0.80 | ACVR1 (0.76) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B | |
| SCHEMBL24409693 | 0.80 | ACVR1 (0.70) | ACVR1BMPR1AACVRL1ACVR1BBMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | ACVR1 12/4885BMPR1A 7/4885ACVRL1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.